SAN DIEGO--(BUSINESS WIRE)--Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse platform technology for antibody drug discovery, today announced the expansion of its existing non-exclusive perpetual license agreement with Eli Lilly and Company. The expanded rights will more broadly enable EIi Lilly to use the AlivaMab Mouse platform for projects with collaborators, including the right to grant sub-licenses to antibody drug candidates much earlier in discovery. Financial terms of the agreement include an undisclosed upfront payment from Eli Lilly. Any potential milestones and royalties on product sales would be paid by the sub-licensees of the AlivaMab Mouse platform.
“This agreement further advances Ablexis’ goal of making AlivaMab Mouse more broadly available for the discovery of the next generation of antibody-based therapeutics,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis and AlivaMab Discovery Services, LLC. “Within the span of just a few weeks the AlivaMab Mouse platform consistently delivers diverse panels of high-affinity, high-potency antibodies with favorable developability qualities and reduced chance of immunogenicity. This represents a significant advantage over in vitro display approaches or other transgenic animal platforms. We look forward to continue making AlivaMab Mouse the platform of choice for experienced antibody drug discoverers and developers.”
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at email@example.com.
AlivaMab Discovery Services was established by Ablexis in response to many prospective partners wanting to outsource discovery to a scientifically-driven organization led by a team with in-the-trenches experience and real understanding of therapeutic antibody discovery and development. AlivaMab Discovery Services leverages the AlivaMab Mouse, developed by Ablexis as the platform for discovery projects conducted on behalf of clients. For more information, visit www.alivamab.com.